Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth - PubMed (original) (raw)
. 1990 Dec 6;348(6301):555-7.
doi: 10.1038/348555a0.
Affiliations
- PMID: 1701033
- DOI: 10.1038/348555a0
Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth
D Ingber et al. Nature. 1990.
Abstract
Neovascularization is critical for the growth of tumours and is a dominant feature in a variety of angiogenic diseases such as diabetic retinopathy, haemangiomas, arthritis and psoriasis. Recognition of the potential therapeutic benefit of controlling unabated capillary growth has led to a search for safe and effective angiogenesis inhibitors. We report here the synthesis of a family of novel inhibitors that are analogues of fumagillin, a naturally secreted antibiotic of Aspergillus fumigatus fresenius. We first isolated this fungus from a contaminated culture of capillary endothelial cells. Purified fumagillin inhibited endothelial cell proliferation in vitro and tumour-induced angiogenesis in vivo; it also inhibited tumour growth in mice, but prolonged administration was limited because it caused severe weight loss. Synthesis of fumagillin analogues yielded potent angiogenesis inhibitors ('angioinhibins') which suppress the growth of a wide variety of tumours with relatively few side-effects.
Similar articles
- Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent.
Kusaka M, Sudo K, Fujita T, Marui S, Itoh F, Ingber D, Folkman J. Kusaka M, et al. Biochem Biophys Res Commun. 1991 Feb 14;174(3):1070-6. doi: 10.1016/0006-291x(91)91529-l. Biochem Biophys Res Commun. 1991. PMID: 1705118 - Synthesis and biological evaluation of novel fumagillin and ovalicin analogues.
Mazitschek R, Huwe A, Giannis A. Mazitschek R, et al. Org Biomol Chem. 2005 Jun 7;3(11):2150-4. doi: 10.1039/b503163j. Epub 2005 Apr 22. Org Biomol Chem. 2005. PMID: 15917904 - Fumagillin inhibits colorectal cancer growth and metastasis in mice: in vivo and in vitro study of anti-angiogenesis.
Hou L, Mori D, Takase Y, Meihua P, Kai K, Tokunaga O. Hou L, et al. Pathol Int. 2009 Jul;59(7):448-61. doi: 10.1111/j.1440-1827.2009.02393.x. Pathol Int. 2009. PMID: 19563408 - [On chance discovery in rational drug design. Aspergillus fumigatus and angiogenesis].
Klein C. Klein C. Pharm Unserer Zeit. 2007;36(6):450-1. doi: 10.1002/pauz.200700242. Pharm Unserer Zeit. 2007. PMID: 17957690 Review. German. - Aspergillus, angiogenesis, and obesity: the story behind beloranib.
Howland RH. Howland RH. J Psychosoc Nurs Ment Health Serv. 2015 Mar;53(3):13-6. doi: 10.3928/02793695-20150219-01. J Psychosoc Nurs Ment Health Serv. 2015. PMID: 25751824 Review.
Cited by
- Tumor angiogenesis and anti-angiogenic therapy.
Guo Z, Jing X, Sun X, Sun S, Yang Y, Cao Y. Guo Z, et al. Chin Med J (Engl). 2024 Sep 5;137(17):2043-2051. doi: 10.1097/CM9.0000000000003231. Epub 2024 Jul 25. Chin Med J (Engl). 2024. PMID: 39051171 Free PMC article. Review. - Pharmacological Characterization of SDX-7320/Evexomostat: A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity.
Cornelius P, Mayes BA, Petersen JS, Turnquist DJ, Dufour PJ, Dannenberg AJ, Shanahan JM, Carver BJ. Cornelius P, et al. Mol Cancer Ther. 2024 May 2;23(5):595-605. doi: 10.1158/1535-7163.MCT-23-0574. Mol Cancer Ther. 2024. PMID: 38530115 Free PMC article. - Blood Vessel-Targeted Therapy in Colorectal Cancer: Current Strategies and Future Perspectives.
Jacobsen A, Siebler J, Grützmann R, Stürzl M, Naschberger E. Jacobsen A, et al. Cancers (Basel). 2024 Feb 22;16(5):890. doi: 10.3390/cancers16050890. Cancers (Basel). 2024. PMID: 38473252 Free PMC article. Review. - Novel Methionine Aminopeptidase 2 Inhibitor M8891 Synergizes with VEGF Receptor Inhibitors to Inhibit Tumor Growth of Renal Cell Carcinoma Models.
Friese-Hamim M, Ortiz Ruiz MJ, Bogatyrova O, Keil M, Rohdich F, Blume B, Leuthner B, Czauderna F, Hahn D, Jabs J, Jaehrling F, Heinrich T, Kellner R, Chan K, Tong AHY, Wienke D, Moffat J, Blaukat A, Zenke FT. Friese-Hamim M, et al. Mol Cancer Ther. 2024 Feb 1;23(2):159-173. doi: 10.1158/1535-7163.MCT-23-0102. Mol Cancer Ther. 2024. PMID: 37940144 Free PMC article. - Preclinical Pharmacokinetics and Translational Pharmacokinetic/Pharmacodynamic Modeling of M8891, a Potent and Reversible Inhibitor of Methionine Aminopeptidase 2.
Lignet F, Friese-Hamim M, Jaehrling F, El Bawab S, Rohdich F. Lignet F, et al. Pharm Res. 2023 Dec;40(12):3011-3023. doi: 10.1007/s11095-023-03611-z. Epub 2023 Oct 5. Pharm Res. 2023. PMID: 37798538 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources